Shamburg News · 8-K filed Oct 23, 2026, 5:01 PM EDT
Cumberland Pharmaceuticals Announces Top-Line Phase 2a Results for Oral Ifetroban in Systemic Sclerosis
CPIX · CUMBERLAND PHARMACEUTICALS INC
- Other event
- Materiality: medium
On October 23, 2026, Cumberland Pharmaceuticals Inc. announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis. The company stated the results support the safety and tolerability of ifetroban in this rare disease population. A copy of the press release was furnished as Exhibit 99.1.
Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001087294-26-000070.
Written from the filing by Shamburg Markets. Figures are as reported by the company.